LifeMine Therapeutics: Funding, Investors & Team (Nov 2026)
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.
LifeMine Therapeutics has raised $413M across 3 funding rounds on record, the most recent a Series E of $188M announced in Aug 2026.
That round is above the $8.8M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
LifeMine Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2026.
LifeMine Therapeutics Funding Rounds
LifeMine Therapeutics raised $50.0M in a Series B announced in Jan 2021.
1.2 years later, a Series C of $175M was announced in Mar 2022.
4.4 years later, a Series E of $188M was announced in Aug 2026.
LifeMine Therapeutics Investors
18 investors are recorded in total; the 5 named above are those the record identifies.
LifeMine Therapeutics Founders and Leadership Team
Contact details for the LifeMine Therapeutics team: 3 of 3 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →LifeMine Therapeutics Funding Compared to Other Biotechnology Startups
LifeMine Therapeutics' latest round of $188M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like LifeMine Therapeutics in Biotechnology and Cambridge
Companies Similar to LifeMine Therapeutics
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus…
Zafrens, a pharmaceutical research organization, focuses on designing life sciences solutions for…
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…
Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…
MEND is a company focused on life sciences, determined to assist individuals in achieving better health…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
LifeMine Therapeutics Funding FAQs
What does LifeMine Therapeutics do?
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.
How much funding has LifeMine Therapeutics raised?
LifeMine Therapeutics has raised $413M across 3 rounds on record. The most recent is a Series E of $188M announced in Aug 2026.
When did LifeMine Therapeutics last raise funding?
LifeMine Therapeutics' most recent funding round on record is a Series E of $188M, announced in Aug 2026.
Who has invested in LifeMine Therapeutics?
Investors on record for LifeMine Therapeutics include RA Capital Management, ARCH Venture Partners, Invus, Fidelity, Foresite Capital. FundedIQ records 18 investors in total.
Who founded LifeMine Therapeutics?
FundedIQ lists Weiqing Zhou (Co-founder & Chief Operating Officer) at LifeMine Therapeutics.
Who is the CEO of LifeMine Therapeutics?
Greg Verdine is listed as CEO at LifeMine Therapeutics.
Where is LifeMine Therapeutics headquartered?
LifeMine Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does LifeMine Therapeutics have?
LifeMine Therapeutics is in the 101-250 employee band.
When was LifeMine Therapeutics founded?
LifeMine Therapeutics was founded in 2016.
How does LifeMine Therapeutics' funding compare to other Biotechnology startups?
LifeMine Therapeutics' latest round of $188M is above the $8.8M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.
About FundedIQ's LifeMine Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for LifeMine Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.